Condition: Neovascular Age-related Macular Degeneration · Sponsor: Skyline Therapeutics (US) Inc.
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
This description comes directly from the study's public registry record.
Yongqin Wang · +86 18616737445 · yongqin.wang@skytx.com
Always discuss trial participation with your own doctor first.
| Retina Vitreous Associates of Florida - Saint Petersburg | St. Petersburg, Florida, United States | Not Yet Recruiting |
| Ophthalmic Consultants of Boston | Boston, Massachusetts, United States | Recruiting |
| Retina Consultants of Texas | Katy, Texas, United States | Recruiting |
| Wagner Kapoor Research Institute | Norfolk, Virginia, United States | Recruiting |
| The Second Hospital Of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Zhejiang Provincial People's Hospital | Hangzhou, Zhejiang, China | Recruiting |
| Eye Hospital, WMU (Zhejiang Eye Hospital) | Wenzhou, Zhejiang, China | Recruiting |
| Beijing Hospital | Beijing, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05986864